BioNTech/Pfizer start clinical trial of Omicron vaccine

Pfizer and BioNTech have enrolled the first participants in a clinical trial of a vaccine tailored to the Omicron coronavirus variant as the companies weigh whether they need to replace their existing Covid-19 jab. The drugmakers on Tuesday said the study would evaluate the safety, tolerability, and efficacy of an Omicron-based vaccine candidate in 1,420 adults aged 18 to 55 years of age.

Read the full article here

Related Articles